Timothy A. Gillespy;Joacy C. Aguiar;Keith John Harris;Elsa A. Dechaux;David Stefany;Sungtaek Lim;Ray Boffey;Charles J. Gardner;Bin Cao;Hazel J. Dyke
发明人:
Sungtaek Lim,Keith John Harris,David Stefany,Charles J. Gardner,Bin Cao,Ray Boffey,Timothy A. Gillespy,Joacy C. Aguiar,Hazel J. Dyke,Elsa A. Dechaux
申请号：
US11735751
公开号：
US08193183B2
申请日:
2007.04.16
申请国别(地区):
US
年份:
2012
代理人:
摘要：
The present invention is directed to a compound of Formula (I)wherein Cy1, Cy2, L1, L2, and R1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).
